Anthera Pharmaceuticals Inc (NASDAQ:ANTH) has been given a consensus rating of “Hold” by the five ratings firms that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $4.19.
A number of research analysts recently weighed in on the company. Roth Capital assumed coverage on Anthera Pharmaceuticals in a research report on Wednesday. They set a “buy” rating and a $10.00 price objective for the company. Zacks Investment Research upgraded Anthera Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.00 target price on the stock in a research note on Tuesday. Finally, ValuEngine upgraded Anthera Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Sunday, December 31st.
Institutional investors and hedge funds have recently modified their holdings of the business. Wedbush Securities Inc. boosted its stake in Anthera Pharmaceuticals by 75.8% during the 3rd quarter. Wedbush Securities Inc. now owns 73,764 shares of the biopharmaceutical company’s stock valued at $106,000 after purchasing an additional 31,800 shares during the last quarter. 683 Capital Management LLC purchased a new stake in Anthera Pharmaceuticals during the 4th quarter valued at $399,000. BVF Inc. IL boosted its stake in Anthera Pharmaceuticals by 20.9% during the 4th quarter. BVF Inc. IL now owns 1,216,403 shares of the biopharmaceutical company’s stock valued at $2,007,000 after purchasing an additional 209,896 shares during the last quarter. Finally, Armistice Capital LLC purchased a new stake in Anthera Pharmaceuticals during the 4th quarter valued at $1,269,000. Institutional investors and hedge funds own 16.44% of the company’s stock.
Anthera Pharmaceuticals (ANTH) remained flat at $$1.69 during mid-day trading on Wednesday. 816,900 shares of the company were exchanged, compared to its average volume of 689,767. Anthera Pharmaceuticals has a 12 month low of $1.20 and a 12 month high of $6.24. The company has a market cap of $23.41, a P/E ratio of -0.31 and a beta of 2.67.
TRADEMARK VIOLATION WARNING: This story was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/02/21/anthera-pharmaceuticals-inc-anth-receives-average-recommendation-of-hold-from-brokerages.html.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.
Receive News & Ratings for Anthera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.